RADIATION & RISK
Bulletin of the National Radiation and Epidemiological Registry
since 1992
About the Journal : 2007 : vol. 16, No. 2-4 : Dynamics of uptake and excretion of Sm-153-oxabifor in patients with bone metastases in the performance of radionuonuclide therapy

Dynamics of uptake and excretion of Sm-153-oxabifor in patients with bone metastases in the performance of radionuonuclide therapy

«Radiation and Risk», 2007, vol. 16, No. 2-4, pp.39-47

Authors

Dolya О.P.1, Klepov А.N.1, Кrylov V.V., Drozdovsky B.Ya., Маtusevich Е.S.I.1
Medical Radiological Research Centre of RAMS, Obninsk.
1Obninsk State Technical University for Nuclear Power Engineering (IATE), Obninsk.

Abstract

The dynamics of 153153Sm excretion was undertaken. Effective half-life of 153Sm-oxabifor in the blood plasma and whole body was determined. Doses to blood, kidneys and urinary bladder wall were estimated. The absorbed doses from 153

Key words
Dynamics of accumulation and excretion, domestic radiopharmaceutical, RFP 153Sm-oxabiphore, bone metastases, radionuclide therapy, effective half-life, dose loads, absorbed doses in organs.

References

Список литературы

1. Dolya O.P., Matusevich E.S., Klepov A.N. Experimental-calculation dosimetric studies in radionuclide therapy of patients with bone metastases. Radiation protection and radionuclide safety in nuclear technologies: Tez. doc. Russian scientific. Conf., IX. Obninsk, 2006. PP. 400-402.

2. Klepov A.N., Kurachenko Yu.A., Levchenko V.A., Matusevich E.S. Application of methods of mathematical modeling in nuclear medicine. Ed. Doct. fiz.-mat. E.S. Matusevich. Obninsk, 2006. 204 pp.

3. The limits of radionuclide intake for workers with ionizing radiation. Publication 30 ICRP. Moscow, Energoatomizdat Publ., 1982.

4. Tsyb A.F., Drozdovskiy B.Ya., Krylov V.V., Kodina G.Ye. Palliative therapy with samarium-oxabiphore, 153 Sm, with metastatic lesions of bones.Med. radiology and radiation safety. 2002. No. 5. PP. 61-68.

5. Buffa F.M., Flux G.D., Guy M.J. et al. A Model-based Method for the Prediction of Whole-body Absorbed Dose and Bone Marrow Toxity. Eur. J. Nucl. Med. Mol. Imagines. 2003. Vol. 30. PP. 1114-1124.

6. Eary J.F., Collins C., Stabin M. et al. Samarium-153-EDTMP Biodistribution and Dosimetry Estimation. J. Nucl. Med. 1993. Vol. 34, No. 7. PP. 1031-1036.

7. Graham M.C., Scher H.I., Boalin G. et al. Rhenium-186-labeled Hydroxyethyliclene Diphosphonate Dosimetry and Dosing Guidelines for the Palliation of Skeletal Metastases from Androgen-independent Prostate Cance. Clinical Cancer Research. 1999. Vol. 5. PP. 1307-1318.

8. Lewington V.L. Cancer Therapy Using Bone-seeking Isotopes. Phys. Med. Biol. 1996. Vol. 41. PP. 2027-2042.

9. Logan K.W., Volkert W.A., Holmes R.A. Radiation Dose Calculations in Persons Receiving Injection of Samarium-153-EDTMP. J. Nucl. Med. 1987. Vol. 28, No. 4. PP. 505-509.

Full-text article (in Russian)